SCHEMBL2340965

SCHEMBL2340965

CC(C)C[C@H](CO)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.54
CA1 P00915 6/20 0.54
CA9 Q16790 4/20 0.54
CA4 P22748 2/20 0.54
MMP2 P08253 6/20 0.49
MMP1 P03956 3/20 0.49
MMP9 P14780 3/20 0.49
MMP13 P45452 3/20 0.49
MMP3 P08254 2/20 0.49
MMP7 P09237 2/20 0.49
CA12 O43570 3/20 0.49
CA14 Q9ULX7 3/20 0.49
HTT P42858 1/20 0.48
MMP8 P22894 3/20 0.48
MMP14 P50281 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CA7 P43166 2/20 0.47
CA3 P07451 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338365 1.00 CA2 (0.54) CA2CA1CA9CA4MMP2
SCHEMBL2338361 1.00 CA2 (0.54) CA2CA1CA9CA4MMP2
SCHEMBL3188052 0.85 MMP2 (0.59) CA2CA1CA9CA4MMP2
SCHEMBL3196493 0.85 MMP2 (0.59) CA2CA1CA9CA4MMP2
SCHEMBL6361881 0.84 CA1 (0.56) CA2CA1CA9CA4MMP2
SCHEMBL8565136 0.82 CA1 (0.51) CA2CA1CA9CA4MMP2
SCHEMBL3179877 0.79 MMP2 (0.44) CA2CA1CA9MMP2MMP1
SCHEMBL3177089 0.78 MMP2 (0.55) CA2CA1CA9CA4MMP2
SCHEMBL8840147 0.78 MMP2 (0.69) MMP2MMP1MMP9MMP13MMP3
SCHEMBL7062306 0.78 MMP2 (0.69) MMP2MMP1MMP9MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE CA2 2555/4885CA1 573/4885CA9 2224/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE CA2 2555/4885CA1 573/4885CA9 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.